Valuation: Autolus Therapeutics plc

Market Cap 428M 376M 346M 324M 608M 40.42B 621M 4.16B 1.61B 19.98B 1.61B 1.57B 69.27B P/E 2026 *
-1.79x
P/E 2027 * -2.47x
Enterprise Value 389M 341M 314M 294M 552M 36.69B 563M 3.78B 1.46B 18.13B 1.46B 1.43B 62.88B EV / Sales 2026 *
3.01x
EV / Sales 2027 * 2.47x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.26%
1 week+6.62%
Current month-13.90%
1 month-4.17%
3 months+24.81%
6 months-3.59%
Current year-19.10%
1 week 1.48
Extreme 1.48
1.68
1 month 1.38
Extreme 1.38
1.89
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Director/Board Member 78 01/08/2014
Director/Board Member 81 15/11/2021
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
03-18Other

U.S. CCO & Country Gen Manager

761,000 0.4581%
03-18Other

Director

240,000 0.1445%
03-18Other

Director

240,000 0.1445%
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%+6.62%-30.30%-37.60% 423M
+2.06%+3.76%+21.48%-19.31% 63.09B
+0.74%+3.52%+53.14%+219.37% 55.61B
-3.10%+34.30%+34.30%+34.30% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+6.97%+9.89%+70.21%-23.28% 29.82B
+12.59%+5.18%+144.26%-44.13% 23.71B
+5.78%+15.81%+60.64%+80.73% 21.48B
-1.25%-1.31%-4.39%+142.42% 16.87B
-0.81%+5.91%+67.70%+124.13% 16.74B
Average +2.19%+5.77%+36.49%+41.77% 30.84B
Weighted average by Cap. +1.77%+5.41%+37.52%+47.24%

Financials

2026 *2027 *
Net sales 129M 113M 104M 97.72M 183M 12.18B 187M 1.25B 485M 6.02B 485M 474M 20.88B 193M 170M 156M 146M 274M 18.24B 280M 1.88B 727M 9.02B 726M 710M 31.27B
Net income -246M -215M -199M -186M -349M -23.17B -356M -2.39B -923M -11.45B -922M -902M -39.71B -192M -168M -155M -145M -272M -18.11B -278M -1.86B -721M -8.95B -721M -705M -31.03B
Net Debt -39.53M -34.66M -31.95M -29.91M -56.09M -3.73B -57.25M -384M -149M -1.84B -148M -145M -6.39B 48.41M 42.45M 39.13M 36.63M 68.69M 4.57B 70.12M 470M 182M 2.26B 182M 178M 7.83B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26/06/26 $1.610 +1.26% 765,841
25/06/26 $1.590 0.00% 606,578
24/06/26 $1.590 -4.22% 1,105,149
23/06/26 $1.660 +11.41% 1,572,640
22/06/26 $1.490 -1.32% 789,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.610USD
Average target price
8.711USD
Spread / Average Target
+441.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock